Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00. Following the sale, the chief operating officer now directly owns 206,286 shares in the company, valued at $6,627,969.18. This trade represents a 4.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jonathan Young also recently made the following trade(s):

• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total transaction of $281,800.00.
• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total transaction of $14,870.24.

Akero Therapeutics Stock Up 4.7 %

Shares of Akero Therapeutics stock opened at $31.11 on Friday. Akero Therapeutics, Inc. has a 52-week low of $15.32 and a 52-week high of $37.00. The company has a 50 day moving average of $30.60 and a 200 day moving average of $26.63. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2.17 billion, a P/E ratio of -8.30 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, research analysts forecast that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. California State Teachers Retirement System boosted its position in shares of Akero Therapeutics by 12.7% during the 1st quarter. California State Teachers Retirement System now owns 54,185 shares of the company’s stock worth $1,369,000 after purchasing an additional 6,113 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in shares of Akero Therapeutics by 30.0% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 28,521 shares of the company’s stock worth $720,000 after purchasing an additional 6,590 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Akero Therapeutics by 191.2% during the 2nd quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock worth $341,000 after purchasing an additional 9,532 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Akero Therapeutics by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock worth $5,894,000 after purchasing an additional 61,988 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Akero Therapeutics by 30.3% during the 2nd quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock worth $2,518,000 after purchasing an additional 24,940 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on AKRO shares. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup began coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.